The contractor proposes to develop pharmacodynamic assays for ERK and ampk.
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201000101C
- Awardee
-
Bioassay Systems LLC UEI NWKBSNNFUFN3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $999,913
Award facts
- Contract value 100% obligated
- $999,913.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Hayward, CA 94545, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute (NCI), a civilian agency, awarded a $999,913.00 definitive cost-no-fee contract to Bioassay Systems LLC, a minority-owned small disadvantaged business, to develop pharmacodynamic assays for ERK and AMPK. The contract has a completion date of September 29, 2012 and was awarded on September 30, 2010. It is a total small business set-aside.
Quick answers
Who was awarded contract HHSN261201000101C?
HHSN261201000101C was awarded to Bioassay Systems LLC by National Cancer Institute (National Institutes of Health) on September 30, 2010.
How much is contract HHSN261201000101C worth?
The government has obligated $999,913 on HHSN261201000101C.
Was contract HHSN261201000101C competed?
The extent of competition for HHSN261201000101C was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award